{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:46:57Z","timestamp":1778244417838,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.yrtph.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T03:02:25Z","timestamp":1491274945000},"page":"356-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"special_numbering":"C","title":["Comparing the incidence of bone tumors in rats chronically exposed\u00a0to the selective PTH type 1 receptor agonist abaloparatide\u00a0or\u00a0PTH(1\u201334)"],"prefix":"10.1016","volume":"86","author":[{"given":"Jacquelin","family":"Jolette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Attalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald G.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nacera","family":"Mellal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabile","family":"Trimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Y.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2017.04.001_bib1","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","article-title":"Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats","volume":"99","author":"Bahar","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.yrtph.2017.04.001_bib3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib4","author":"FDA"},{"key":"10.1016\/j.yrtph.2017.04.001_bib5","author":"FDA"},{"key":"10.1016\/j.yrtph.2017.04.001_bib6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.yrtph.2017.04.001_bib7","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1158\/0008-5472.CAN-09-0194","article-title":"Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ","volume":"69","author":"Fleming","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.yrtph.2017.04.001_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jnci\/93.3.234","article-title":"Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases","volume":"93","author":"Henderson","year":"2001","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.yrtph.2017.04.001_bib10","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-05-2814","article-title":"Parathyroid hormone-related protein localization in breast cancers predict improved prognosis","volume":"66","author":"Henderson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yrtph.2017.04.001_bib12","first-page":"29","article-title":"Hypercalcemia of malignancy in hospitalized patients","volume":"42","author":"Jibrin","year":"2006","journal-title":"Hosp. Phys."},{"key":"10.1016\/j.yrtph.2017.04.001_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2017.04.001_bib14","series-title":"Forteo voluntary patient registry: 6-year progress on a prospective osteosarcoma surveillance study. 22nd Annual Meeting of the International Society of Clinical Densitometry (ISCD)","author":"Krohn","year":"2016"},{"key":"10.1016\/j.yrtph.2017.04.001_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yrtph.2017.04.001_bib16","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1172\/JCI46134","article-title":"PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target","volume":"121","author":"Li","year":"2011","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.yrtph.2017.04.001_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.1617","article-title":"Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine","volume":"27","author":"McCauley","year":"2012","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.yrtph.2017.04.001_bib19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.yrtph.2017.04.001_bib20","first-page":"311","article-title":"Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments","author":"Peto","year":"1980","journal-title":"IARC Monogr. Eval. Carcinog. Risk Chem. Hum. Suppl."},{"key":"10.1016\/j.yrtph.2017.04.001_bib21","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yrtph.2017.04.001_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1359\/jbmr.2002.17.7.1151","article-title":"Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women","volume":"17","author":"Tashjian","year":"2002","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1359\/jbmr.081233","article-title":"PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation","volume":"24","author":"Theman","year":"2009","journal-title":"J.\u00a0Bone Min. Res."},{"key":"10.1016\/j.yrtph.2017.04.001_bib24","first-page":"565","article-title":"Hyperostosis in the F344 rat","volume":"vol. 2","author":"Thurman","year":"1994"},{"key":"10.1016\/j.yrtph.2017.04.001_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2017.04.001_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2017.04.001_bib27","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J.\u00a0Clin. Endocrinol. Metab."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230017300880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230017300880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T20:21:55Z","timestamp":1535919715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230017300880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"alternative-id":["S0273230017300880"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2017.04.001","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the incidence of bone tumors in rats chronically exposed\u00a0to the selective PTH type 1 receptor agonist abaloparatide\u00a0or\u00a0PTH(1\u201334)","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}